Publications by authors named "Rhj Mathijssen"

Claim this Profile
I
Impact of geriatric impairments on outcomes of single-agent immunotherapy in solid tumors.
Asli Özkan, Karlijn de Joode, Ellen Kapiteijn, Marije Slingerland, Stephanie Zunder, Ron H J Mathijssen

Int J Cancer· March 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OATP2B1 Deficiency Ameliorates Irinotecan-Induced Gastrointestinal Toxicity.
Hanieh Taheri, Peter de Bruijn, Yang Li, Nicholas R Kleinert, Kara N Corps, Ron H J Mathijssen

Clin Transl Sci· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Capacity and cost benefits of subcutaneous versus intravenous pertuzumab/trastuzumab: The EASE-SC study.
Michiel Zietse, Jacky Hu, Esther R van Staveren, Leontine E A M M Spierings, Agnes Jager, Ron H J Mathijssen

Breast· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapeutic Drug Monitoring of Oral Targeted Anticancer Drugs: Achievements, Experiences, Challenges, and the Path Forward.
Maud B A van der Kleij, Karolijn W M Groot Beumer, Stijn L W Koolen, Ron H J Mathijssen, Neeltje Steeghs

Ther Drug Monit· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of immune checkpoint inhibitors on gonadal function in patients with solid tumors.
B van Dijk, K de Joode, Y V Louwers, H M W Verheul, R H J Mathijssen

ESMO Open· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma.
Ruben Malmberg, Maaike M Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Ron H J Mathijssen

Clin Pharmacol Ther· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to letter Re: Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.
Asli Özkan, Karlijn de Joode, Ellen Kapiteijn, Marije Slingerland, Stephanie Zunder, Ron H J Mathijssen

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter Re: Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels.
Niels Heersche, Ron H J Mathijssen, Annemieke Cats, Henk-Jan Guchelaar, Jonathan E Knikman

Eur J Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of intraperitoneal irinotecan with systemic capecitabine and oxaliplatin for patients with gastric peritoneal metastases.
Niels A D Guchelaar, Marion W Tops-Welten, Pieter C van der Sluis, Bo J Noordman, Stijn L W Koolen, Ron H J Mathijssen

Biomed Pharmacother· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis.
Michiel Zietse, Thirza Kooijman, Ruben Malmberg, Leontine E A M M Spierings, Agnes Jager, Ron H J Mathijssen

JCO Oncol Pract· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folinic Acid Prophylaxis and Dose Adjustments Enable Safe Treatment with Pemetrexed in Patients with Renal Impairment.
Nikki de Rouw, Leila-Sophie Otten, Mart P Kicken, Berber Piet, Bonne Biesma, Ron H J Mathijssen

Clin Pharmacol Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thromboembolism in patients with melanoma receiving immune checkpoint inhibitors: incidence and risk factors.
D C H van Dorst, M M Hofman, R M de Waal, E Oomen-de Hoop, K de Joode, R H J Mathijssen

Immunooncol Technol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Semaglutide impairs bioavailability of alectinib: a note of warning based on a cross-over pharmacokinetic drug-drug interaction study.
Niels Heersche, Daan A C Lanser, Esther Oomen-de Hoop, Attila Içli, Peter de Bruijn, Ron H J Mathijssen

Cancer Commun (Lond)· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mechanisms of anti-VEGF therapy-induced kidney injury: current insights and future perspectives in combination with immune checkpoint inhibitors.
Tom J J Uyl, Abigail Ngo, Delaney Pratt, Isabella Cortez, Ron H J Mathijssen

Am J Physiol Renal Physiol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Clinical Pharmacological Perspective on Intraperitoneal Chemotherapy.
Pascale C S Rietveld, Niels A D Guchelaar, Sebastiaan D T Sassen, Birgit C P Koch, Ron H J Mathijssen

Drugs· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors.
Asli Özkan, Karlijn de Joode, Ellen Kapiteijn, Marije Slingerland, Stephanie Zunder, Ron H J Mathijssen

Eur J Cancer· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic boosting of olaparib: Study protocol of a multicentre, open-label, randomised, non-inferiority trial (PROACTIVE-B).
Joanneke K Overbeek, Niels A D Guchelaar, Ma Ida Mohmaed Ali, Muriëlle Sark, Carolien Hovenier, Ron H J Mathijssen

Contemp Clin Trials Commun· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Errata: Environmental Impact Assessment of Intravenous Versus Subcutaneous Monoclonal Antibodies: A Carbon Footprint Analysis.
Michiel Zietse, Thirza Kooijman, Ruben Malmberg, Leontine E A M M Spierings, Agnes Jager, Ron H J Mathijssen

JCO Oncol Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-individualisation of fluoropyrimidines based on pre-treatment serum uracil levels: the Alpe2U study.
Jonathan E Knikman, Mirjam de With, Niels Heersche, Marta Lopez-Yurda, Arnold Baars, Ron H J Mathijssen

Eur J Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology.
Bram C Agema, Birgit C P Koch, Ron H J Mathijssen, Stijn L W Koolen

Drugs· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug release from docetaxel-entrapped core-crosslinked polymeric micelles: A population pharmacokinetic modelling approach based on clinical data.
Pascale C S Rietveld, Stijn L W Koolen, Stefan Zeiser, Cristianne J F Rijcken, Martijn van Noort, Ron H J Mathijssen

Biomed Pharmacother· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Onset and progression of atherosclerosis in patients with melanoma treated with immune checkpoint inhibitors.
Daan C H van Dorst, Tom J J Uyl, Astrid A M Van der Veldt, Timy Andrawes, Arjen Joosse, Ron H J Mathijssen

J Immunother Cancer· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Omission of dexamethasone in paclitaxel premedication regimens: protocol of the multicentre, randomised, non-inferiority DEXASTOP trial.
Michiel Zietse, Luuk C Aalders, Leontine E A M M Spierings, Nikki De Rouw, Wouter Dercksen, Ron H J Mathijssen

BMJ Open· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The prognostic value of peritoneal metastases in patients with gastric cancer: a nationwide population-based study.
Niels A D Guchelaar, Micha J de Neijs, Bo J Noordman, Heilida E C Graaf, Irene E G van Hellemond, Ron H J Mathijssen

EClinicalMedicine· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trifluridine-tipiracil in previously treated patients with oestrogen receptor-positive, HER2-negative metastatic breast cancer (BOOG 2019-01 TIBET trial): a single-arm, multicentre, phase 2 trial.
Niels A D Guchelaar, Ron H J Mathijssen, Maaike de Boer, Marlies L van Bekkum, Joan B Heijns

EClinicalMedicine· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis